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Figure 1: En bloc resection specimen of the proximal fibula of a 
43 year old female, containing a lobulated bluish white, 
translucent tumour (4.5 x 2 x 1.9 cm) located centrally within the 
medullary cavity, consistent with central chondrosarcoma.  
Classification 
Note: Approximately 90% of chondrosarcomas are 
histologically of the conventional type; in addition to 
conventional chondrosarcoma, some rare variants with 
distinctive microscopic and clinical features are 
discerned: clear cell chondrosarcoma (1%), 
mesenchymal chondrosarcoma (2%), juxtacortical 
chondrosarcoma (2%) and extra-skeletal myxoid 
chondrosarcoma (5%). Furthermore, dedifferentiated 
chondrosarcoma is a relatively rare high grade sarcoma 
next to a low-grade conventional malignant cartilage-
forming tumor, comprising 6-10% of all 
chondrosarcomas. Conventional chondrosarcoma can 
be categorized according to their location in bone.  
 
Figure 2: Corresponding macro-slice showing a lobular 
architecture, and endosteal cortical thinning. Cytonuclear 
appearance can be more readily appreciated in figure 3. 










Figure 3: Micrograph displaying low cellularity with limited cytonuclear atypia, and a high amount of chondroid matrix surrounding tumor 
cells consistent with a grade I chondrosarcoma. Note the presence of a binucleated cell. 
 
The majority of chondrosarcomas (75%) are located 
centrally within the medullary cavity (central 
chondrosarcoma), whereas a minority (15%) develops 
from the surface of bone (peripheral chondrosarcoma) 
as a result of malignant transformation within the 
cartilaginous cap of a solitary or hereditary pre-exist nt 
osteochondroma. 
Clinics and pathology 
Epidemiology 
Primary malignant bone tumours occur 1/100,000, of 
which 17-24% consists of chondrosarcoma; the 
majority of patients are between 35 and 60 years old 
with equal sex distribution. 
Clinics 
Compared to benign cartilaginous tumours, 
chondrosarcomas more frequently present with pain 
and tenderness; they usually develop in the trunk, 
pelvis and long bones. 
Pathology 
There are no apparent cytonuclear differences between 
central and peripheral conventional chondrosarcomas 
and both are histologically classified into three grades 
using the criteria of Evans et al. 
Grade I chondrosarcomas demonstrate low cellularity, 
limited cytonuclear atypia, few multinucleated cells, a  
 
mainly chondroid matrix and the absence of mitoses; 
In contrast, grade III chondrosarcomas are highly 
cellular, with nuclear polymorphism, mitoses and a 
mostly myxoid matrix; 
Increasing histological grade is correlated with higher 
metastatic potential; it is considered difficult to assess 
the histological grade of cartilaginous tumours and to 
reliably distinguish between benign tumours and those 
of low-grade malignancy. 
Treatment 
Because chondrosarcoma is highly resistant to 
chemotherapy and radiotherapy, surgical treatment is 
the only option for curative treatment. 
Evolution 
The majority of central chondrosarcomas are 
considered to arise de novo and malignant 
transformation of solitary enchondroma is extremely 
rare (<1%); in patients demonstrating multiple 
enchondromas, such as Ollier's disease, the incidence 
of secondary central chondrosarcoma is much higher 
(30-35%); peripheral chondrosarcomas usually 
originate from the cartilaginous cap of an 
osteochondroma; malignant transformation is low in 
solitary osteochondromas (<1%) but is estimated to 
occur in 1-5% of cases of hereditary multiple 
exostoses; furthermore, an occasional recurrent 
chondrosarcoma may exhibit a higher grade of  
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malignancy than the original neoplasm, suggesting that 
tumours may additionally progress from low to high 
grade. 
Prognosis 
Metastasis in chondrosarcoma highly depends on the 
histological grade of malignancy; grade I 
chondrosarcomas demonstrate local recurrence, but 
seldom metastasize; grade II chondrosarcomas 
demonstrate metastases in 10-30% of the cases, 
whereas grade III chondrosarcomas demonstrate 
metasases in the majority of cases; in contrast to 
chondrosarcomas located elsewhere in the skeleton, 
those located in the phalanx behave as a locally 
aggressive lesion with minimal metastatic potential. 
Cytogenetics 
Cytogenetics Morphological 
Extra-skeletal myxoid chondrosarcoma, comprising 5% 
of all chondrosarcomas, is characterized by a recipo al 
translocation t(9;22)(q22;q12), fusing the EWS to the
CHN gene. 
Cytogenetic analysis on a heterogeneous group of 
chondrosarcomas revealed that structural aberrations of 
chromosomes 1, 6, 9, 12 and 15 and numerical 
aberrations of chromosomes 5, 7, 8 and 18 were most
frequent; abnormalities of chromosome 1 and 7 were 
confined to malignant cartilaginous tumours; like in 
other mesenchymal neoplasms, band 12q13-15 is 
prominently involved in the aberrations; the presence 
of chromosome aberrations was found to strongly 
correlate with increasing histological grade; complex 
aberrations were mainly seen in the high-grade 
chondrosarcomas. 
Cytogenetics Molecular 
In a comparative study of central and peripheral 
chondrosarcomas, 19 of 20 peripheral chondrosarcomas 
showed LOH at all loci (EXT, EXTL, 13q14, 17p13, 
9p21 and chromosome 10) tested while only 3 of 12 
central chondrosarcomas exhibited LOH, restricted to 
9p21, 10, 13q14 and 17p13. DNA-flow-cytometry 
demonstrated a wide variation in the ploidy status in 
peripheral chondrosarcomas (DNA-indices 0.56 - 2.01), 
whereas central chondrosarcomas were predominantly 
peridiploid; these results indicate that peripheral 
chondrosarcomas, arising secondarily to an exostosis, 
may obtain genetic alterations during malignant 
transformation, with subsequent genetic instability as 
demonstrated by a high percentage of LOH and a wide
variation in ploidy status; in contrast, peridiploidy and 
a low percentage of LOH in central tumors suggest that 
a different oncogenic molecular mechanism may be 
operative; no mutations in the EXT1 and EXT2 genes 
were found in secondary peripheral chondrosarcoma. 
Investigating both the cartilaginous as well as the high-
grade malignant component of dedifferentiated 
chondrosarcoma, an identical somatic 6 bp deletion in 
exon 7 of p53 and loss of the same copy of 
chromosome 13 provided compelling evidence for a 
common origin instead of the 'collision tumor' theory; 
in addition, many different genetic alterations were 
found, indicating that the separation of the two clnes 
is a relatively early event in the histogenesis of 
dedifferentiated chondrosarcoma. 
Unfortunately, most other genetic analyses on 
chondrosarcoma were performed on a heterogeneous 
group including all different subtypes of 
chondrosarcoma; ploidy-analysis of chondrosarcomas 
has been described and aneuploidy is more frequently 
found in high-grade chondrosarcomas; two series of 
chondrosarcomas (n=23 and n=50) studied by CGH 
revealed extensive genetic aberrations; the majority f 
these changes were gains of whole chromosomes or 
whole chromosome arms, most frequent at 20q (32-
38%), 20p (24-31%), and 14q23-qter (24-28%); a 
correlation between gain at 8q24.1 and shorter overall 
survival was reported; amplification of the c-myc 
proto-oncogene, located at 8q24, was found in four of 
12 chondrosarcomas, and was not associated with any 
clinicopathological features; the only recurrent high-
level amplification, seen in two tumours (7%), affected 
the minimal common region 12cen-q15; although both 
cytogenetic analysis and CGH point at 12cen-q15, 
CDK4, MDM2 and SAS were not frequently amplified 
in chondrosarcoma. 
Partial allelotypings of a heterogeneous group of 
chondrosarcoma revealed that in addition to LOH at the 
EXT-loci on chromosomes 8 (4/17) and 11 (7/17), 
LOH was found at 10q11 (12/18), the Rb - (9/25) and
p53-locus (7/28). Overexpression of the p53 protein 
and TP53 mutations have been observed mainly in 
high-grade chondrosarcomas, suggesting that the p53 
gene could play a role in the progression of 
chondrosarcoma. 
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